EGFR and colorectal carcinoma: The addition of epidermal growth factor receptor (EGFR) targeting monoclonal antibodies (mABs) cetuximab and panitumumab to treatment protocols has improved survival rates in patients with metastatic colorectal cancer (CRC) as has been shown in numerous clinical trials [1, 2].